大理学院学报
大理學院學報
대이학원학보
JOURNAL OF DALI COLLEGE
2013年
12期
20-22
,共3页
三联疗法%微生态制剂%幽门螺杆菌
三聯療法%微生態製劑%幽門螺桿菌
삼련요법%미생태제제%유문라간균
triple therapy%probiotics%Helicobacter pylori
目的：探讨微生态制剂联合兰索拉唑、克拉霉素片、阿莫西林胶囊在幽门螺杆菌感染治疗中的疗效及安全性。方法：将118例慢性胃炎或消化性溃疡且经快速尿素酶试验、病理切片染色镜检、13C-尿素酶呼气试验检测幽门螺杆菌任何两项阳性患者随机分为联合治疗组60例，常规三联方根除治疗（兰索拉唑+克拉霉素+阿莫西林胶囊）加0.35 g双歧杆菌片0.7 g 2次/d，口服，与抗菌药物间隔2 h服用，疗程14 d。对照组58例，常规三联方根除治疗（兰索拉唑+克拉霉素+阿莫西林胶囊）不使用双歧杆菌，疗程14 d。治疗结束4周后复查13C-尿素酶呼气试验。比较两组根除率及不良反应发生率。结果：联合治疗组根除率80%，对照组根除率77.5%，两组间差异无统计学意义（P＞0.05），但是联合治疗组不良反应发生率6.7%与对照组不良反应发生率22.4%比较差异具有统计学意义（P＜0.05）。结论：常规三联疗法结合双歧杆菌片在幽门螺杆菌感染治疗中不良作用少，患者依从性较好，值得临床推广和应用。
目的：探討微生態製劑聯閤蘭索拉唑、剋拉黴素片、阿莫西林膠囊在幽門螺桿菌感染治療中的療效及安全性。方法：將118例慢性胃炎或消化性潰瘍且經快速尿素酶試驗、病理切片染色鏡檢、13C-尿素酶呼氣試驗檢測幽門螺桿菌任何兩項暘性患者隨機分為聯閤治療組60例，常規三聯方根除治療（蘭索拉唑+剋拉黴素+阿莫西林膠囊）加0.35 g雙歧桿菌片0.7 g 2次/d，口服，與抗菌藥物間隔2 h服用，療程14 d。對照組58例，常規三聯方根除治療（蘭索拉唑+剋拉黴素+阿莫西林膠囊）不使用雙歧桿菌，療程14 d。治療結束4週後複查13C-尿素酶呼氣試驗。比較兩組根除率及不良反應髮生率。結果：聯閤治療組根除率80%，對照組根除率77.5%，兩組間差異無統計學意義（P＞0.05），但是聯閤治療組不良反應髮生率6.7%與對照組不良反應髮生率22.4%比較差異具有統計學意義（P＜0.05）。結論：常規三聯療法結閤雙歧桿菌片在幽門螺桿菌感染治療中不良作用少，患者依從性較好，值得臨床推廣和應用。
목적：탐토미생태제제연합란색랍서、극랍매소편、아막서림효낭재유문라간균감염치료중적료효급안전성。방법：장118례만성위염혹소화성궤양차경쾌속뇨소매시험、병리절편염색경검、13C-뇨소매호기시험검측유문라간균임하량항양성환자수궤분위연합치료조60례，상규삼련방근제치료（란색랍서+극랍매소+아막서림효낭）가0.35 g쌍기간균편0.7 g 2차/d，구복，여항균약물간격2 h복용，료정14 d。대조조58례，상규삼련방근제치료（란색랍서+극랍매소+아막서림효낭）불사용쌍기간균，료정14 d。치료결속4주후복사13C-뇨소매호기시험。비교량조근제솔급불량반응발생솔。결과：연합치료조근제솔80%，대조조근제솔77.5%，량조간차이무통계학의의（P＞0.05），단시연합치료조불량반응발생솔6.7%여대조조불량반응발생솔22.4%비교차이구유통계학의의（P＜0.05）。결론：상규삼련요법결합쌍기간균편재유문라간균감염치료중불량작용소，환자의종성교호，치득림상추엄화응용。
Objective: To study the efficacy and safety of triple therapy (lansoprazole, clarithromycin tablets, and amoxicillin capsules)with probiotics in the treatment of helicobacter pylori infection. Methods:118 cases of chronic gastritis or peptic ulcer with any two positive results of rapid urease test, pathological staining, 13C- urease expiratory test were randomly divided into two groups:60 cases of combined treatment group, lansoprazole clarithromycin and Amoxicillin capsules with 0.35 g of bifidobacterium 0.7 g Po, bid, and 2 h interval taking antibiotics, course 14 d, 58 cases of the control group, lansoprazole clarithromycin and Amoxicillin capsules without Bifidobacterium, course 14 d. Repeat 13C- urea breath test after 4 weeks. Compare the eradication rate and adverse reaction rate of two groups. Results: the eradication rate of treatment group was 80%; the control group the eradication rate was 77.5%, there was no significant difference between the two groups (P>0.05), but the adverse reaction incidence were statistically significant different (P<0.05) between treatment group 6.7% and control group 22.4%. Conclusion: Triple therapy with bifidobacterium tablets in the treatment of Hp infection which has less side effect, is worthy of clinical application.
